Introducing Signant Health
CRF Bracket, formed by the 2018 merger of CRF Health and Bracket, launched as Signant Health - uniting eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies, and Endpoint Quality into a patient-centric suite.
“The best technology in clinical research succeeds in the background,” said Mike Nolte, CEO of Signant Health. “We work to be expert, with proven solutions and scientific support that simplify research for patients, sponsors and CROs. I’m humbled to be a part of our customers’ important work, proud of the Signant Health team and excited to continue to innovate along every step of the patient journey.”
Signant Health combines a comprehensive, united suite of proven technologies with developers, project managers, data analysts, scientists and clinicians.
“The new Signant brand reflects our desire to help separate signal from noise at the intersection of science and technology and to never forget that our customers’ significant work matters locally and globally,” added Nolte. ”In 2018, CRF Health and Bracket brought together industry-leading technology and analytics solutions, renowned executive and scientific leaders, and 20 years of experience delivering exemplary service to life science companies worldwide. The birth of Signant Health marks the next phase in our journey and unlocks extraordinary opportunities to improve the patient’s journey as well.”
To learn more about Signant Health’s solutions, visit www.signanthealth.com
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
